Company intelligence / Profile preview

Devlife

Yokohama, Kanagawa, Japan

Ownership: Private
Development stage: Other

Overview

DevLife is a clinical-stage biotechnology company based in Japan that focuses on developing novel small molecule immunotherapies for cancer. The company's lead asset, DL-001, is a potent and selective Toll-like receptor 7 (TLR7) agonist designed to activate the innate immune system to induce anti-tumor activity. DevLife is currently evaluating DL-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Devlife.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Devlife.

Explore the full profile